secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-06-02T10:09:32+00:00
Accession:  0001140361-26-023625
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics posts updated corporate presentation; specific content not available in filing excerpt
--------------------------------------------------------------------------------

- Presentation dated June 2026 made available on company's website on June 1, 2026.
- Presentation describes Gyre as a biopharma company focused on fibrosis, inflammatory diseases, and cancer.
- Filing includes only the title slide; full presentation content is not included in the provided exhibit text.
- Investors should refer to the full presentation on the company's website for detailed updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126023625/0001140361-26-023625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126023625/ef20075381_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-023625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer